OPTN

OptiNose (OPTN)

OptiNose Inc

일자:

규정 관련뉴스

텍스트 검색:

정렬 기준:

규정 외 뉴스

검색 관련기사 보기:NASDAQ:OPTN

1 2 3 4 5 6 7 8 9 10 다음 >>

일자	시간	출처	헤드라인	심볼	기업
2024/05/18	01:00	GlobeNewswire Inc.	Optinose to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ	NASDAQ:OPTN	OptiNose Inc
2024/05/14	22:01	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:OPTN	OptiNose Inc
2024/05/14	20:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OPTN	OptiNose Inc
2024/05/14	20:00	GlobeNewswire Inc.	Optinose Reports First Quarter 2024 Financial Results and Recent Operational Highlights	NASDAQ:OPTN	OptiNose Inc
2024/05/11	03:56	GlobeNewswire Inc.	Optinose Announces Reporting Date for First Quarter 2024 Financial Results	NASDAQ:OPTN	OptiNose Inc
2024/05/09	20:09	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:OPTN	OptiNose Inc
2024/05/09	20:04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OPTN	OptiNose Inc
2024/05/09	20:03	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:OPTN	OptiNose Inc
2024/05/09	20:02	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:OPTN	OptiNose Inc
2024/05/09	20:00	GlobeNewswire Inc.	Optinose Announces $55 Million Registered Direct Offering	NASDAQ:OPTN	OptiNose Inc
2024/04/25	20:00	GlobeNewswire Inc.	Optinose Provides Corporate Update on XHANCE Launch and Outlook and Announces Preliminary First Quarter 2024 XHANCE Net Revenue of $14.9 million	NASDAQ:OPTN	OptiNose Inc
2024/04/05	05:01	GlobeNewswire Inc.	Optinose to Present at the Needham Virtual Healthcare Conference	NASDAQ:OPTN	OptiNose Inc
2024/03/16	04:34	GlobeNewswire Inc.	XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps	NASDAQ:OPTN	OptiNose Inc
2024/03/09	06:10	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OPTN	OptiNose Inc
2024/03/08	06:32	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:OPTN	OptiNose Inc
2024/03/07	21:01	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:OPTN	OptiNose Inc
2024/03/07	21:00	GlobeNewswire Inc.	Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights	NASDAQ:OPTN	OptiNose Inc
2024/03/07	21:00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OPTN	OptiNose Inc
2024/03/01	06:40	GlobeNewswire Inc.	Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results	NASDAQ:OPTN	OptiNose Inc
2024/03/01	06:07	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:OPTN	OptiNose Inc
2024/03/01	06:06	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:OPTN	OptiNose Inc
2024/03/01	06:05	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:OPTN	OptiNose Inc
2024/03/01	06:04	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:OPTN	OptiNose Inc
2024/02/23	21:08	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:OPTN	OptiNose Inc
2024/02/23	06:28	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:OPTN	OptiNose Inc
2024/02/15	10:48	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:OPTN	OptiNose Inc
2024/02/14	07:16	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:OPTN	OptiNose Inc
2024/02/02	04:43	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:OPTN	OptiNose Inc
2024/01/31	06:05	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:OPTN	OptiNose Inc
2024/01/19	02:00	GlobeNewswire Inc.	Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice	NASDAQ:OPTN	OptiNose Inc